Top 24 alternative sites to freeline.life
-
synconaltd.com
-
gyroscopetx.com
-
haemophilia.ie
-
hobsonprior.com
-
askbio.com
-
genetherapy-conference.com
-
capsida.com
-
miltenyibiomedicine.com
-
graphitebio.com
-
genetherapy-muscular.com
-
horizondiscovery.com
-
nbhl.co.jp
-
delpor.com
-
cellestia.com
-
genscriptprobio.com
-
tmedpharma.com
-
ocugen.com
-
primedmedcentre.co.za
-
sylentis.com
-
altimmune.com
-
vectivbio.com
-
tricida.com
-
algiax.com
-
elvium.ca
Syncona – building the next generation of global leaders in life science
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Home - Gyroscope
Vision for LifeDEVELOPING ONE-TIME GENE THERAPIES FOR EYE DISEASES Vision for LifeDEVELOPING ONE-TIME GENE THERAPIES FOR EYE DISEASES 3 Welcome to Gyroscope We are discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world. Our ultimate goal for our patients is – Vision For Life. […]
Author: GyroscopeTX
Welcome to haemophilia.ie - Irish Haemophilia Society
Representing people living with haemophilia, von willebrand’s and other inherited bleeding disorders The Irish Haemophilia Society represents the interests of people with haemophilia, von Willebrand’s disease and other inherited bleeding disorders. We provide information, education, publications, outreach and support, advocacy, hospital Read more >
Author: IrishHaemophiliaSoc
Home | Hobson Prior
Experts in life sciences recruitment Focused on finding and placing exceptional...
Author: Author Matthew Vickers
AskBio - AAV Gene Therapy Technology & Therapeutics
AskBio is a leading, clinical-stage gene therapy company dedicated to developing AAV gene therapies for genetic and complex disorders. Learn more about our gene therapy technology and current clinical trials.
4th Annual Gene Therapy for Rare Disorders 2021 | Home
Gene Therapy for Rare Disorders focuses on overcoming the commercial challenges **** developers face when delivering gene therapies to market
Home - Capsida
We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications.
Personalized cell and gene therapy | Miltenyi Biomedicine
Miltenyi Biomedicine GmbH develops innovative cell and gene therapies. We are focused on bringing cancer treatments and regenerative therapies to patients.
Graphite Bio | Next-Generation Gene Editing to Cure Serious Diseases
Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
Author: Rajeshl
2nd Gene Therapy for Muscular Disorders Summit | April 2022 | Home
The 2nd Gene Therapy for Muscular Disorders Summit will focus on overcoming the challenges of developing genetic therapies targeting muscular disorders, including Duchenne Muscular Dystrophy, Limb-Girdle Muscular Dystrophy, Pompe Disease and X-Linked Myotubular Myopathy.
Gene editing and gene modulation for life sciences
Horizon Discovery drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine. With more than a decade of experience in the engineering of cell lines, Horizon offers innovative tools and services based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines. Horizon is headquartered in Cambridge, UK with offices in USA and Japan.
NBHL ltd.
NB Health Laboratory Co. Ltd. (NBHL) is a biotechnology company dedicated to discovering, developing and commercializing innovative medicines to treat respiratory diseases, chronic inflammation and central nervous system disorders.
Delpor.com – Breakthrough Discoveries for a Better Life
News View All Delpor is a clinical-stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapies for chronic diseases. The Company is focusing on CNS conditions including Schizophrenia, Opioid Use Disorder, Spasticity, Parkinson’s, Alzheimer’s, and MS.
Author: Delpor Admin
Cellestia, modulating gene expression
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-**** resistant cancers.
Integrated Protein and Antibody CDMO Solution-Gene and Cell Therapy - GenScript ProBio
GenScript ProBio is the world's leading biotech company which provides Gene Therapy vector, Cell Therapy vector etc. Find one-stop antibody **** development solutions with GMP platform. Call Us Today.
Targeted Medical Pharma, Inc. - Innovating Medicine for Better Patient Care
Targeted Medical Pharma, Inc. (OTC:TRGM) is a publicly traded, Los Angeles-based biotechnology company that develops amino acid based medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.
Ocugen, Inc. – Pursuing Innovative Ocular Biotherapeutics
Ocugen, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.
Primed Medcentre
Why Primed Medcentre Primed Medcentre is a medical practice situated in Bryanston, Sandton that provides leading, innovative, and alternative therapies that offer patients comprehensive non-surgical pain and chronic disease management. At Primed Medcentre we are focused on bringing you the best
Author: Siteadmin
SYLENTIS S.A. - RNAi biopharmaceuticals
SYLENTIS, biotechnology company focused on the development of new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology. Addressed diseases in its pipeline includes dry eye, retina diseases, glaucoma or allergies. SYLENTIS is one of the pioneer companies devoted to siRNA, with one of the most advanced siRNA design technologies worldwide, researching on an extense range of Ophtalmical Therapeutic areas and indications. Most advanced experimental drugs: Bamosiran and Tivanisiran.
Other sites like freeline life
Altimmune a clinical stage biopharmaceutical company
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B, and conjugated immunostimulants for the treatment of cancer. In addition, we are developing intranasal vaccine & therapeutic candidates for anthrax, influenza and COVID-19.
VectivBio | Transforming Lives
Life-Transforming Medicines for Patients Living with Severe Rare Diseases We are a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. Learn More About Us Our Focus We use a patient-centric approach to identify and develop transformative medicines for the treatment […]
Tricida | Working to Turn the Tide on Metabolic Acidosis
Tricida, Inc., is a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies. Tricida’s lead investigational **** candidate, TRC101, represents a first-in-class approach to the treatment of metabolic acidosis, a common complication of chronic kidney disease (CKD) that can result in increased mortality, accelerated progression of kidney disease, progressive muscle breakdown and exacerbation of bone disease.
Home | Algiax Pharmaceuticals GmbH
News – Events About Us Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain. Next […]
Elvium Life Sciences – Elvium Life Sciences is an innovative life sciences company focused on improving the lives of patients.
About Elvium We are Elvium Life Sciences, a pharmaceutical company passionately committed to improving the health and quality of life of Canadians through innovative medicines in specific therapeutic disease areas of need and importance. Learn More Our Products Elvium Life Sciences focuses on our existing
Author: Taro
